Fampridine and Acetazolamide in EA2 and Related Familial EA: A Prospective Randomized Placebo-Controlled Trial.
Journal
Neurology. Clinical practice
ISSN: 2163-0402
Titre abrégé: Neurol Clin Pract
Pays: United States
ID NLM: 101577149
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
25
06
2020
accepted:
22
10
2020
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
7
9
2021
Statut:
ppublish
Résumé
To determine the efficacy and safety of the treatment with prolonged-release 4-aminopyridine (fampridine) and acetazolamide for patients with episodic ataxia type 2 (EA2), patients with EA2 were treated with a random sequence of fampridine, acetazolamide, and placebo in a 3-period crossover trial. A total of 30 patients with EA2 (8 female; aged 20-71 years; 18 genetically confirmed, 4 with a positive family history, 8 with the clinical diagnosis) were enrolled in this phase III, randomized, double-blind, placebo-controlled, 3-period crossover trial. Each period lasted 12 weeks with a 4-week washout period. Each patient received a random sequence of 20 mg/d fampridine, 750 mg/d acetazolamide, and placebo. The primary end point was the number of attacks during the last 30 days within the 12-week treatment period. Participants, caregivers, and those assessing the outcomes were blinded to the intervention. Compared with placebo, fampridine reduced the number of attacks to 63% (95% CI 54%-74%) and acetazolamide to 52% (95% CI 46%-60%). A total of 39 (26.5%) adverse events were observed under treatment with fampridine (mostly tingling paresthesia and fatigue), 66 (44.9%) happened under acetazolamide (mostly taste disturbance and gastrointestinal complaints), and 42 (28.6%) under placebo (mostly gastrointestinal complaints). Both fampridine and acetazolamide significantly reduce the number of attacks in patients with EA2 and related EA in comparison to placebo. Fampridine 10 mg twice daily had fewer side effects than acetazolamide 250 mg 3 times daily. The trial was registered with DRKS.de (DRKS00005258) and EudraCT (2013-000107-17). This study was supported by the Federal Ministry of Education and Research (BMBF) (grant number 01EO0901). Fampridine (study medication) was provided by Biogen Idec. Class II evidence.
Identifiants
pubmed: 34484942
doi: 10.1212/CPJ.0000000000001017
pii: NEURCLINPRACT2020056713
pmc: PMC8382428
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e438-e446Informations de copyright
© 2021 American Academy of Neurology.
Références
Neurology. 2004 Jan 13;62(1):17-22
pubmed: 14718690
Eur J Paediatr Neurol. 2016 Sep;20(5):772-6
pubmed: 27328862
Ann Neurol. 2010 Oct;68(4):494-502
pubmed: 20976768
Int J Mol Med. 2003 Feb;11(2):187-9
pubmed: 12525875
Cell. 1996 Nov 1;87(3):543-52
pubmed: 8898206
Neurology. 1999 Jun 10;52(9):1816-21
pubmed: 10371528
Lancet. 2009 Feb 28;373(9665):732-8
pubmed: 19249634
Brain. 2007 Oct;130(Pt 10):2484-93
pubmed: 17575281
Neurology. 1983 Sep;33(9):1212-4
pubmed: 6684259
J Neurol. 2013 Feb;260(2):668-9
pubmed: 23183922
Neurology. 1978 Dec;28(12):1259-64
pubmed: 366453
Neurology. 2004 May 11;62(9):1623-5
pubmed: 15136697
Handb Clin Neurol. 2018;155:205-215
pubmed: 29891059
J Neurosci. 2012 Oct 31;32(44):15533-46
pubmed: 23115190
Neurology. 2012 Nov 20;79(21):2115-21
pubmed: 23077024
Neurology. 2018 Mar 6;90(10):464-471
pubmed: 29440566
Neurology. 2011 Jul 19;77(3):269-75
pubmed: 21734179
Neurotherapeutics. 2007 Apr;4(2):267-73
pubmed: 17395137
Mov Disord. 2012 Jan;27(1):125-31
pubmed: 21997342